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1. Introduction 
Amyloid flbrils from several patients with secondary 
amyloidosis or amyloidosis associated with Familial 
Mediterrean Fever (FMF), when treated with dilute 
acid yield a major low molecular component which 
appears to be similar in all, and unrelated to any known 
immunoglobulin. 
In an effort to separate the protein subunit present 
in amyloid fibrils from mucopolysaccharides, amyloid 
fibrils isolated by the method of Pras et al. [ 1 ] were 
extracted with dilute acid. This procedure yielded a 
low molecular weight substance which migrated as a 
single band on disc electrophoresis, had a molecular 
weight of around 6,000 daltons, bound Congo red, 
and could be made to assume again a fibrillar appear- 
ance which however differed from that of typical amy- 
loid fibrills [2] . In the present study we present the 
partial amino acid sequences of this component from 
two patients and show them to be identical. 
2. Materials and methods 
The acid soluble low molecular weight fraction was 
extracted from amyloid fibrils isolated from the liver 
of a patient with Hodgkin’s disease and the spleen of a 
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patient with FMF by treating the fibrils with 0.02 M 
HCl for 1 hr at 60”. After centrifugation, the super- 
natant which contained 40-50% of the dry weight 
was dialyzed against 0.15 M NaCl and then against 
distilled water. The material was redissolved in 0.02 
M HCI and further purified by vacuum dialysis. The 
dialysate was then lyophilized prior to use [2]. 
N-terminal analyses were done by the dansyl 
chloride method [ 31 and identified on polyamide 
thin-layer plates. The partial ammo acid sequence was 
determined in a Beckman Model 890 sequencer by the 
method of Edman and Begg [4]. Released thiazolinone 
derivatives were converted to phenythiohydantoin 
(PTH) derivatives with 1 N HCl at 80” for 10 min and 
were identified as such or as the silylated derivative by 
gas chromatography using a Hewlett Packard gas 
chromatograph [5] and by ammo acid analysis after 
hydrolysis using a Beckman 12 1 amino acid analyzer. 
3. Results 
Table 1 lists the amino acid composition of the 2 
preparations which appear to be similar but not iden- 
tical. Both samples are devoid of cysteine, poor in 
threonine and rich in aspartic acid, phenylalanine, 
glycine, alanine, and arginine. The amino terminal 
residue of both was serine although small amounts of 
arginine were also identified in the first step of the 
Edman degradation. 
Fig. 1 lists the amino acid sequence of the first 33 
residues of the Hodgkin’s protein, 21 residues of the 
FMF protein and compares them to the 24 residues of 
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Table 1 
Amino acid composition of acid soluble fraction from 
2 human amyloid fibrils. 
Amino acid Number of residues found* 
FMF Hodgkins 
Lysine 
Histidine 
Arginine 
Aspartic acid 
Threonine 
Serine 
Glutamic acid 
Proline 
Glycine 
Alanine 
Half Cystine 
Valine 
Methionine** 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Tryptophan** 
2.0 2.3 
1.1 1.8 
7.0 6.6 
9.1 7.3 
0.9 0.2 
4.6 4.0 
6.3 5.4 
1.0 0.8 
7.6 6.6 
11.6 10.0 
__- ___ 
0.9 1.1 
(21 (2) 
2.0 2.0 
2.2 1.2 
3.7 3.4 
4.7 5.0 
+ 
* Mean of 3 analyses after 21 hr hydrolysis. 
** Identified from amino acid sequence analysis in fig. 1. 
protein A from a patient with tuberculosis recently 
sequenced by Benditt et al. [6]. It is apparent that all 
3 appear to be identical in the regions examined. 
4. Discussion 
From the data presented in this study it would 
appear that a protein seemingly unrelated to any 
known immunoglubulin may constitute up to 50% of 
the dry weight of amyloid fibrils isolated from 2 sub- 
jects with amyloidosis associated with Hodgkin’s dis- 
ease and FMF. This material appears to be identical to 
protein A found in secondary amyloidosis, one sample 
of which was recently partially sequenced by Benditt 
et al. [6,7] . Thus it seems likely that it may constitute 
a major component of amyloid substance of diverse 
origin [2,6,7] . This component seems to be present 
in addition to the immunoglubulin fragments demon- 
strated by Glenner et al. [8] since examination of the 
peptide map of one of these proteins (FMF) indicates 
the presence of peptides characteristic of the acid sol- 
uble fraction as well as those which appear to be com- 
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mon to light chains. References 
Whether this protein is synthesized and deposited 
as such, or represents a fragment of a larger protein 
remains to be determined. The heterogeneity and 
presence of arginine at the amino terminus raise the 
possibility that it is the product of proteolytic digestion 
of a larger protein. 
The presence of this protein in 3 subjects, a similar 
one which has not yet been fully characterized in sev- 
eral others [2,7], taken together with the ability to 
bind Congo red and to assume a fibrillar appearance, 
suggest an important role in the genesis of amyloid. 
If the same protein can be identified also in primary 
and myeloma associated amyloid it seems possible 
that it may represent a basic defect common to all 
amyloid. 
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